Speeches & presentations
Search through our archive of speeches and presentations from conferences and events.
Filter by
-
Investor and Analyst call on GSK’165 aGM-CSF data presented at ACR
On Tuesday, 23 October 2018, Dr Hal Barron, Chief Scientific Officer and President R&D and Luke Miels, President, GSK Global Pharmaceuticals hosted an investor conference call following the presentation of efficacy and safety data on GSK3196165, GSK's anti-GM-CSF antibody in development for Rheumatoid Arthritis at the 2018 American College of Rheumatology (ACR). The call also featured participation from an external expert in rheumatology and GSK’s Medicine Development Lead for GSK’165.
-
Consumer Healthcare investor event, New Jersey
Brian McNamara, CEO GSK Consumer Healthcare, and members of his leadership team hosted an investor event to review the Consumer Healthcare business. This event included a tour of our Shopper Science, Consumer Sensory and R&D labs, as well as presentations from Brian McNamara, Marc Speichert, SVP Digital and Richard Slater, SVP R&D, followed by a Q&A session.
-
CECP CEO Investor Forum
Emma Walmsley, CEO, spoke at CECP’s CEO Investor Forum on Thursday 20 September 2018 about the steps we are taking to build trust – one of our three long-term priorities – and drive sustainable business performance.
Analyst webcast -
Bank of America Merrill Lynch Global Healthcare Conference, London
Emma Walmsley, CEO, gave a presentation at the Bank of America Merrill Lynch Global Healthcare Conference in London on Thursday 13 September 2018 in which she provided an overview of GSK’s priorities and progress made during 2018.
Analyst webcast -
GEMINI Results of HIV 2 Drug Regimen Investor & Analyst Update
On Tuesday, 24 July 2018, GSK hosted an investor conference call following the presentation of the full set of scientific and clinical data on GSK’s 2 drug regimen of dolutegravir plus lamiviudine (GEMINI studies) in treatment naïve HIV patients at the 22nd International AIDS Conference.
The call was hosted by David Redfern, GSK Chief of Strategy and Chairman of ViiV Healthcare, Deborah Waterhouse, CEO of ViiV Healthcare, John Pottage, Chief Scientific & Medical Officer of ViiV Healthcare, and Kimberly Smith, VP Global Research & Medical Strategy of ViiV Healthcare.
-
Goldman Sachs 39th Annual Healthcare Conference, California
David Redfern, Chief Strategy Officer, hosted a fireside chat at the Goldman Sachs 39th Annual Healthcare Conference in Rancho Palos Verdes, California on Wednesday 13 June, in which he provided an overview of GSK’s priorities and progress made during 2018.
Analyst webcast -
Jefferies 2018 Healthcare Conference, New York City
David Redfern, Chief Strategy Officer, hosted a fireside chat at the Jefferies 2018 Healthcare Conference in New York City on Wednesday 6 June, in which he provided an overview of GSK’s priorities and progress made during 2018.
Please access the webcast using Google Chrome.
Analyst webcast -
Consumer Healthcare Update, London
On Tuesday, 27 March 2018, GSK reached an agreement with Novartis to acquire full ownership of the Consumer Healthcare business. A call for investors and analysts was hosted by Emma Walmsley, Chief Executive Officer, Simon Dingemans, Chief Financial Officer and Brian McNamara, CEO, Consumer Healthcare.
- Consumer Healthcare Update - Analyst call slides PDF - 929.5KB
- Consumer Healthcare Update - Analyst call transcript PDF - 65.4KB
-
36th annual JP Morgan Healthcare Conference, San Francisco, USA
Emma Walmsley, CEO, gave a presentation at the 36th annual JP Morgan Healthcare Conference in San Francisco about our business outlook, as well as our latest product approvals and advances in our pipeline.
- 2018 JPM Emma Walmsley presentation PDF - 699.0KB
- 2018 JPM Emma Walmsley presentation transcript PDF - 54.7KB
- 2018 JPM Emma Walmsley Q&A transcript PDF - 65.9KB
-
GSK Oncology Investor & Analyst Update
On Tuesday, 12 December 2017, GSK hosted an investor conference call following the presentation of scientific and clinical data on GSK2857916, GSK's anti-BCMA (B-cell Maturation Antigen) antibody-drug conjugate presented at the 59th American Society of Hematology (ASH) annual meeting.
The call was hosted by Luke Miels, President, GSK Global Pharmaceuticals and Axel Hoos, SVP and Therapy Area Head of Oncology R&D. The call also featured participation from an external expert in multiple myeloma. -
Citi Global Healthcare Conference, New York
Axel Hoos, SVP – Oncology R&D, participated in a fireside chat at the Citi Global Healthcare Conference on December 7 in New York.
Analyst webcast -
Evercore conference, Boston
David Redfern, Chief Strategy Officer and Chairman of ViiV Healthcare, Deborah Waterhouse, CEO of ViiV Healthcare and Kim Smith, Vice President, Global Medical Strategy, ViiV Healthcare, participated in a fireside chat at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference in Boston on Thursday, November 30.
Analyst webcast -
Consumer Healthcare investor event
Brian McNamara, CEO GSK Consumer Healthcare, and members of his leadership team hosted an investor event to review the Consumer Healthcare business. This event included a tour of our Shopper Science and Consumer Sensory labs, as well as presentations from Brian McNamara and Richard Slater, SVP, R&D Consumer Healthcare, followed by a Q&A session.
-
Investor event, London 2017
The investor event outlined the Group’s key priorities including presentations from Emma Walmsley, CEO, and Simon Dingemans, CFO.
- Emma Walmsley slides: Key priorities PDF - 864.3KB
- Simon Dingemans slides: Q2 and financial outlook PDF - 509.3KB
- Investor event full transcript PDF - 173.6KB
-
Cowen 37th Annual Healthcare Conference
Axel Hoos, SVP – Oncology R&D, gave a presentation at the Cowen and Company 37th Annual Health Care Conference in Boston. Axel provided an overview of GSK’s Oncology strategy and pipeline.
- Cowen 37th Annual Healthcare Conference - slides PDF - 1.3MB
- Cowen 37th Annual Healthcare Conference - transcript PDF - 84.2KB
-
Investor event at CROI 2017, Seattle
ViiV Healthcare Chairman David Redfern, CEO Dominique Limet and Chief Scientific and Medical Officer John Pottage, hosted an investor event following the presentation of the SWORD Phase III data at the Conference on Retroviral and Opportunistic Infections.
-
35th annual JP Morgan Healthcare Conference, San Francisco, USA
Dr Patrick Vallance, President, R&D gave a presentation at the 35th annual JP Morgan Healthcare Conference in San Francisco, providing an overview of the company’s pharmaceutical pipeline.
- 2017 JPM Patrick Vallance presentation PDF - 1.1MB
- 2017 JPM Patrick Vallance transcript PDF - 176.9KB
-
Meet the Vaccines management
Luc Debruyne and his leadership team hosted an investor event to review the Vaccines business. This event included a tour of the Wavre site, presentations from Luc Debruyne, Thomas Breuer, Manu Hanon and John McGrath, followed by a Q&A session.
-
HIV and ViiV Healthcare presentation to Goldman Sachs
Seminar on the evolving scientific and commercial landscape for HIV and ViiV Healthcare. Presentation by Dr Dominique Limet and Dr John Pottage followed by a Q&A session.
-
Meet The Respiratory Management event
Prior to the 2016 ERS conference, senior respiratory leaders Eric Dube, Neil Barnes and Dave Allen hosted an investor event with presentations and a Q&A session to review the Respiratory business.
